# Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

> **NCT04964505** · PHASE1 · TERMINATED · sponsor: **Brian Jonas** · enrollment: 16 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Uproleselan
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04964505
- **Lead sponsor:** Brian Jonas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-02
- **Primary completion:** 2024-10-04
- **Final completion:** 2025-10-07
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04964505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04964505, "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04964505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*